多西他赛、奥沙利铂和替吉奥新辅助化疗方案治疗晚期胃癌的效果分析

Effect Analysis of Neoadjuvant Chemotherapy Regimens of Docetaxel,Oxaliplatin and Tegafur in the Treatment of Advancedgastric Cancer

目的:探讨多西他赛、奥沙利铂和替吉奥新辅助化疗方案治疗晚期胃癌的效果。方法:选取某院收治的82例晚期胃癌患者,按随机数字表法将其分为对照组和试验组各41例,对照组给予多西他赛、奥沙利铂和氟尿嘧啶化疗方案,试验组将氟尿嘧啶替换为替吉奥胶囊,两组均随访1年,比较两组血管因子及细胞侵袭因子水平;比较两组生存状态及疾病进展、不良反应发生情况。结果:与治疗前比,两组治疗后IGF-1、VEGF、MMP-9、MMP-2水平降低,且试验组低于对照组(P<0.05)。试验组1年生存率及生存周期分别为75.61%、11.326个月,高于对照组的60.98%、7.212个月(P<0.01);干预后试验组1年未进展率及平均生存期分别为68.29%、10.317个月,明显高于对照组的53.66%、8.092个月(P<0.01)。治疗期间,试验组胃肠道反应及周围神经炎的发生率分别为12.19%、14.63%,明显低于对照组的31.71%、41.46%(P<0.05)。结论:多西他赛、奥沙利铂和替吉奥新辅助化疗方案可以降低晚期胃癌患者血管因子及细胞侵袭因子水平,改善其生存周期,不良反应低,安全性好。

Objective:To explore the effects of docetaxel,oxaliplatin and tegafur neoadjuvant chemotherapy regimens in the treatment of advanced gastric cancer.Methods:82 patients with advanced gastric cancer admitted to a hospital were selected and divided into control group(n=41) and the test group(n=41).The control group was given docetaxel,oxaliplatin,and fluorouracil chemotherapy programs,and the test group replaced fluorouracil with tegafur capsules.Both groups were followed up for 1 year.The levels of vascular factors and cell invasion factors,survival status,disease progression,and incidence of adverse reactions in the two groups were compared.Results:Compared with before treatment,the levels of IGF-1,VEGF,MMP-9,and MMP-2 in the two groups were decreased after treatment,and the test group was lower than the control group(P<0.05).The 1-year survival rate and survival cycle of the test group were 75.61% and 11.326 months,respectively,which were higher than those of the control group(60.98%,7.212 months)(P<0.01).The 1-year non-progression rate and average survival time in the test group after the intervention were 68.29% and 10.317 months,respectively,significantly higher than those in the control group(53.66%,8.092 months)(P<0.01).During the treatment period,the incidences of gastrointestinal reactions and peripheral neuritis in the test group were 12.19% and 14.63%,respectively,which were significantly lower than those in the control group(31.71%,41.46%)(P<0.05).Conclusion:The neoadjuvant chemotherapy regimens of docetaxel,oxaliplatin and tegafur can reduce the levels of vascular factors and cell invasion factors in patients with advanced gastric cancer,and improve their survival cycle,with low adverse reactions and good safety.